Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Table 4
Most common adverse events (≥2% in rimonabant-treated patients and ≥1% in placebo).
Placebo ()
Rimonabant (20 mg) ()
Patients with any TEAE
184 (56.8%)
210 (66.0%)
Patients with any serious TEAE
15 (4.6%)
10 (3.1%)
Patients with any TEAE leading to death
0
0
Patients permanently discontinued due to TEAE
9 (2.8%)
10 (3.1%)
Most common adverse events
Gastrointestinal disorders
Nausea
13 (4.0%)
37 (11.6%)
Diarrhea
14 (4.3%)
24 (7.5%)
Dyspepsia
2 (0.6%)
10 (3.1%)
Vomiting
3 (0.9%)
9 (2.8%)
Nervous system disorders
Dizziness
31 (9.6%)
34 (10.7%)
Psychiatric disorders
Insomnia
11 (3.4%)
14 (4.4%)
Depression
3 (0.9%)
13 (4.1%)
Anxiety
5 (1.5%)
12 (3.8%)
Skin and subcutaneous tissue disorders
Hyperhidrosis
3 (0.9%)
7 (2.2%)
Cardiac disorders
Palpitations
3 (0.9%)
15 (4.7%)
General disorders and administration site conditions
Fatigue
3 (0.9%)
8 (2.5%)
Infections and infestations
URTI
29 (9.0%)
34 (10.7%)
TEAE: treatment-emergent adverse event; URTI: upper respiratory tract infection. Note: TEAEs included all adverse events with an onset date during treatment exposure and up to 75 days following the last study drug intake.
